% | $
Quotes you view appear here for quick access.

Talon Therapeutics, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • tredleon tredleon Oct 8, 2009 7:53 PM Flag

    Blindsided by hnab management

    Exactly - there were several other options that would have been better for existing shareholders - sell the company, partner Marquibo, etc. - instead we get the ultra-dilutive offering. You expect something like this when you have a drug that has a high risk of approval, but all the signs are that Marquibo will easily win approval. They could have done much better than this offering in protecting the value for existing shareholders.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • They had no choice, and as bad as this is (yes we bent over), there were no other options to keep this company from going bankrupt.

      The likelihood of success with marqibo is very small, and the investors know this, so why shouldn't they get a huge discount and on top of that additional penny warrants.

      I think HNAB is lucky to get anything.